Core Technology Platform

核心技术平台

AI + mRNA full-stack independent R&D, complete loop from algorithm to product

AI + mRNA 全栈自研,从算法到产品的完整闭环

0
Patents Issued
已授权专利
0
SCI Publications
SCI 论文
0
Core Platforms
核心平台

核心技术 · AI + mRNA 全栈平台

Core Technology · AI + mRNA Full-Stack Platform

从靶点发现到产品交付的完整技术闭环

Complete technology loop from target discovery to product delivery

上游技术:领先行业,降维打击
UPSTREAM: Industry-Leading AI
AI 主导抗原预测体系
提高研发效率 2 个数量级
AI-driven antigen prediction
boosts R&D efficiency by 100×
好药物是"算"出来的
"Good drugs are computed"
反向疫苗学
抗原筛查
Reverse
Vaccinology
»
抗原结构
设计
Antigen
Design
»
mRNA 序列
表达架构优化
mRNA Sequence
Optimization
下游技术:独门绝技,出奇制胜
DOWNSTREAM: Proprietary Process
动保免疫净化服务
毛利 >70%
Veterinary immunization
gross margin >70%
成本已具备商用条件
Cost-ready for commercialization
低成本
mRNA 工艺
Low-Cost
mRNA Process
»
低成本
LNP 投递剂型
Low-Cost
LNP Delivery
»
工艺体系
便于放量
Scalable
Manufacturing
🧬
基因组分析
Genomics
🔬
蛋白结构预测
Protein Structure
💉
mRNA 设计
mRNA Design
🫧
LNP 递送
LNP Delivery
🐾
动物疫苗
Veterinary Vaccine
🏥
人用药物
Human Therapeutics
核心价值亮点 Core Value Highlights
☑ 效率革命☑ Efficiency Revolution

AI 主导的抗原预测体系
好药物是"算"出来的

AI-driven antigen prediction
Good drugs are computed

☑ 壁垒深厚☑ Strong Moat

21 项发明专利获批、11 项在审
12 篇 SCI 论文,10 项软件著作权

21 patents granted, 11 pending
12 SCI papers, 10 software copyrights

☑ 商用落地☑ Commercial Ready

自主 IP 业内领先,支持跨物种应用
冻干 2-8℃ 稳定保存 2 年以上

Leading proprietary IP, cross-species ready
Lyophilized, stable 2+ years at 2-8°C

01 AI PredictionAI 预测 02 LNP DeliveryLNP 递送 03 mRNA DesignmRNA 设计 04 GMP SystemGMP 体系 05 Lyophilization冻干技术 06 IP Portfolio知识产权
01

AI Neoantigen Prediction

AI 新生抗原预测

Advanced deep learning architecture combining CNN, LSTM, and large language models with molecular simulation for superior prediction accuracy

结合 CNN、LSTM、大语言模型与分子模拟的先进深度学习架构,实现优异的预测精度

AI算力配置与精确制导
0
Cross-Species Prediction Accuracy
跨物种预测准确率
0
MHC-II Epitope PPV
MHC-II 表位预测性能
Algorithm Architecture
算法架构
CNN + LSTM + Large Model + AlphaFold & Molecular Simulation
CNN + LSTM + 大模型 + AlphaFold & 分子模拟
Structural Biology
结构生物学
MHC pocket constraints & TCR binding information
MHC 口袋约束及 TCR 结合信息
Multi-Species
多物种预测
Pigs, chickens, ducks with >80% accuracy
猪、鸡、鸭等多个物种,准确率 >80%
MHC Coverage
MHC 覆盖
Both MHC I & II with leading domestic performance
MHC I & II 均可准确预测,国内领先
Validation
验证
Multiple animal studies & ~100 clinical samples
多个动物实验及近百临床样本验证
Publications
已发表
Front Oncol., Science Advances (IF>17)
Technical Parameter 技术参数 TheraRNA 澄实生物 BioNTech
Sequencing Technology 测序技术 3rd Gen Long-Read 全长三代测序 2nd Gen Short-Read
Capture Method 捕获 Translatome 翻译组 WES + RNAseq
Antigen Prediction 抗原预测 MHC I + II MHC I + II MHC I
Patient Response 患者响应率 80% (4/5) 80% (4/5) 50% (8/16)
Positive Epitope Rate 表位阳性率 19.6% (11/56) 19.6% (11/56) 10.4% (25/240)

Data Sources

数据来源

Public IEDB data + ~1,000 internal tumor clinical datasets + Collaborative 1M+ immunopeptidome data

IEDB 公开数据 + 自有近千肿瘤临床数据 + 合作百万条免疫多肽组学数据

Computing Cores
计算核心
~400
CPU
Memory
内存
~32T
Storage
存储
~1000T
GPU Arsenal
GPU 阵列
H100
+ GTX 3090 & 4090
02

Proprietary LNP Delivery System

自研 LNP 递送系统

Ionizable cationic lipids with 4 delivery patents, validated against Moderna's SM-102 standard

自研可电离阳离子脂质,4 项递送体系专利,与莫德纳 SM-102 进行对标验证

Purity
纯度
≥90%
Gel Electrophoresis
凝胶电泳法
Particle Size
粒径
80-120nm
Dynamic Light Scattering
动态光散射
PDI
多分散指数
≤0.2
DLS Measurement
DLS 测量
Encapsulation
包封率
≥90%
Fluorescent RNA assay
核酸荧光检测
SM-102 Comparison
SM-102 对标
Equivalent
Guinea pig neutralizing antibodies match or exceed SM-102
中和抗体水平达到/超过 SM-102
Patents
专利
4
Delivery system patents issued
递送体系专利
03

mRNA Molecular Design

mRNA 分子设计

Patent-protected sequence optimization and protein expression prediction using proprietary algorithms

专有算法驱动的受专利保护的序列优化与蛋白表达预测

Dynamic Programming mRNA Optimization
动态规划 mRNA 序列优化
Patent: CN119785885A — Sequence optimization for enhanced expression
专利:CN119785885A — 增强表达的序列优化
Deep Learning Protein Prediction
深度学习蛋白翻译预测
Patent: CN119785882A — mRNA to protein product prediction
专利:CN119785882A — mRNA 翻译蛋白质产物预测
Linear RNA Innovation
线性 RNA 创新
Patent: CN116262926B — Non-capped linear RNA recombinant nucleic acid molecules
专利:CN116262926B — 非加帽线性 RNA 重组核酸分子
Exosome Secretion
外泌体分泌
Fusion molecules promoting membrane protein secretion via exosomes
可促使膜固定蛋白随外泌体分泌的融合分子
FcRn Enhanced Immunity
FcRn 增强免疫
Recombinant vaccines improving cellular immune response levels
提高细胞免疫水平的重组疫苗
Stability & Manufacturing
稳定性与制造
Improved mRNA stability reduces manufacturing development complexity
提高 mRNA 稳定性,降低工艺开发难度
04

GMP Manufacturing System

GMP 工艺体系

Self-developed equipment, infrastructure, and processes for scalable mRNA vaccine production

自研生产设备、基础设施与工艺,实现 mRNA 疫苗规模化生产

Daily Capacity
单台日产能
200K
Doses per production unit
头份/生产单元
Annual Capacity
年产能
1B
Doses per year
剂/年
Facility Scale
厂房规模
26K m²
Jiangxi Pingxiang, 54 acres
江西萍乡 54 亩
GMP Compliance
GMP 符合
2026
Static certification target
静态验收完成时间
Operation Model
运营模式
Asset-Light
Government-built facility
政府代建轻资产
Market Position
市场地位
First
Domestic mRNA animal vaccine GMP
国内首批 mRNA 动物疫苗 GMP

Development Economics

开发经济学

R&D Cost per Product: ¥3-7M — approximately 1/3 of traditional technology pathway costs

单个产品研发成本:300-700 万 — 约为传统技术路线成本的 1/3

05

Lyophilization Technology

冻干技术

Temperature-stable formulation enabling global distribution at standard storage conditions

常温稳定制剂,实现全球常温物流与存储

自主IP递送+生产双突破
2-8°C
冻干制剂稳定保存 2 年+
Lyophilized stable 2+ years
<10%
冻干损失率,超级稳定
Loss rate, ultra-stable
≥90%
纯度·包封率·核心指标
Purity & encapsulation rate
06

Intellectual Property Portfolio

知识产权总览

Comprehensive patent protection and scientific publications supporting core technology platforms

为核心技术平台提供全面专利保护与科学验证

0
Patents
Issued
已授权
专利
10+
Patents
Under Review
审批中
专利
0
SCI
Publications
SCI
论文
0
Software
Copyrights
软件著作权